Honoka Tamori

Honoka Tamori

Auto-generated profile, based on publicly available information

Honoka Tamori

National Institute of Public Health (M Takai, H Tamori, and M Tanaka), Center for Outcomes Research and Economic Evaluation for Health, Saitama, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in JMIR Human Factors
Verified
Journal Article
Open access
HTHonoka Tamori
Honoka Tamori
HYHiroko YAMASHINA
Hiroko YAMASHINA
MMMasami MUKAI
Masami MUKAI
YMYasuhiro Morii
Yasuhiro Morii
TSTeppei Suzuki
Teppei Suzuki
KOKatsuhiko Ogasawara
Katsuhiko Ogasawara
Background: The use of artificial intelligence (AI) in the medical industry promises many benefits, so AI has been introduced to medical practice primarily in developed countries. In Japan, the government is preparing for the rollout of AI in the medical industry. This rollout depends on doctors and the public accepting the technology. Therefore it is necessary to consider acceptance among doctors and among the public. However, little is known about the acceptance of AI in medicine in Japan. Objective: This study aimed to obtain detailed data on the acceptance of AI in medicine by comparing the acceptance among Japanese doctors with that among the Japanese public. Methods: We conducted an online survey, and the responses of doctors and members of the public were compared. AI in medicine was defined as the use of AI to determine diagnosis and treatment without requiring a doctor. A questionnaire was prepared referred to as the unified theory of acceptance and use of technology, a model of behavior toward new technologies. It comprises 20 items, and each item was rated on a five-point scale. Using this questionnaire, we conducted an online survey in 2018 among 399 doctors and 600 members of the public. The sample-wide responses were analyzed, and then the responses of the doctors were compared with those of the public using t tests. Results: Regarding the sample-wide responses (N=999), 653 (65.4%) of the respondents believed, in the future, AI in medicine would be necessary, whereas only 447 (44.7%) expressed an intention to use AI-driven medicine. Additionally, 730 (73.1%) believed that regulatory legislation was necessary, and 734 (73.5%) were concerned about where accountability lies. Regarding the comparison between doctors and the public, doctors (mean 3.43, SD 1.00) were more likely than members of the public (mean 3.23, SD 0.92) to express intention to use AI-driven medicine (P<.001), suggesting that optimism about AI in medicine is greater among doctors compared to the public. Conclusions: Many of the respondents were optimistic about the role of AI in medicine. However, when asked whether they would like to use AI-driven medicine, they tended to give a negative response. This trend suggests that concerns about the lack of regulation and about accountability hindered acceptance. Additionally, the results revealed that doctors were more enthusiastic than members of the public regarding AI-driven medicine. For the successful implementation of AI in medicine, it would be necessary to inform the public and doctors about the relevant laws and to take measures to remove their concerns about them.

2 October 2020 in JMIR Preprints
Verified
Preprint
Open access
HTHonoka Tamori
Honoka Tamori
HYHiroko YAMASHINA
Hiroko YAMASHINA
MMMasami MUKAI
Masami MUKAI
YMYasuhiro Morii
Yasuhiro Morii
TSTeppei Suzuki
Teppei Suzuki
KOKatsuhiko Ogasawara
Katsuhiko Ogasawara
BACKGROUND The use of artificial intelligence (AI) in the medical industry promises many benefits, so AI has been introduced to medical practice primarily in developed countries. In Japan, the government is preparing for the rollout of AI in the medical industry. This rollout depends on doctors and the public accepting the technology. Therefore it is necessary to consider acceptance among doctors and among the public. However, little is known about the acceptance of AI in medicine in Japan. OBJECTIVE This study aimed to obtain detailed data on the acceptance of AI in medicine by comparing the acceptance among Japanese doctors with that among the Japanese public. METHODS We conducted an online survey, and the responses of doctors and members of the public were compared. AI in medicine was defined as the use of AI to determine diagnosis and treatment without requiring a doctor. A questionnaire was prepared referred to as the unified theory of acceptance and use of technology, a model of behavior toward new technologies. It comprises 20 items, and each item was rated on a five-point scale. Using this questionnaire, we conducted an online survey in 2018 among 399 doctors and 600 members of the public. The sample-wide responses were analyzed, and then the responses of the doctors were compared with those of the public using t tests. RESULTS Regarding the sample-wide responses (N=999), 653 (65.4%) of the respondents believed, in the future, AI in medicine would be necessary, whereas only 447 (44.7%) expressed an intention to use AI-driven medicine. Additionally, 730 (73.1%) believed that regulatory legislation was necessary, and 734 (73.5%) were concerned about where accountability lies. Regarding the comparison between doctors and the public, doctors (mean 3.43, SD 1.00) were more likely than members of the public (mean 3.23, SD 0.92) to express intention to use AI-driven medicine (P<.001), suggesting that optimism about AI in medicine is greater among doctors compared to the public. CONCLUSIONS Many of the respondents were optimistic about the role of AI in medicine. However, when asked whether they would like to use AI-driven medicine, they tended to give a negative response. This trend suggests that concerns about the lack of regulation and about accountability hindered acceptance. Additionally, the results revealed that doctors were more enthusiastic than members of the public regarding AI-driven medicine. For the successful implementation of AI in medicine, it would be necessary to inform the public and doctors about the relevant laws and to take measures to remove their concerns about them.

12 November 2026 in Journal of Medical Economics
Verified
Journal Article
Open access
HTHonoka Tamori
Honoka Tamori
TOToshiya Osanai
Toshiya Osanai
HUHaruto Uchino
Haruto Uchino
SISachie Inoue
Sachie Inoue
YMYasuhiro Morii
Yasuhiro Morii
MFMiki Fujimura
Miki Fujimura
With continuous advances in medical technology and the rapid aging of populations worldwide, healthcare expenditures have increased in Japan [1]. Under these tightening fiscal constraints, health t...

28 February 2026 in Academic Pediatrics
Verified
Journal Article
Open access
KHKimiko Honda
Kimiko Honda
MTManami Takai
Manami Takai
MHMegumi Hirono
Megumi Hirono
EKEmi Kamono
Emi Kamono
HTHonoka Tamori
Honoka Tamori
EHEri Hoshino
Eri Hoshino
To map existing research on the quality of life (QOL) of parents and other informal caregivers of children with chronic illnesses, describe study characteristics, caregiver and patient populations, and identify the instruments used to measure QOL and their characteristics. Six databases (MEDLINE, EMBASE, Cochrane Library, PsycINFO, CINAHL, Ichushi) were searched up to October 2024. Eligible studies included parents and other informal caregivers of children with chronic illnesses assessed with multidomain QOL questionnaires. Data on study design, populations, conditions, instruments, and outcomes were extracted, and results were synthesized descriptively using counts and percentages. Searches identified 3356 records, of which 409 quantitative studies met the inclusion criteria. The number of publications notably increased since 2020. Most studies were observational (73%) and cross-sectional (62%) with small sample sizes. The most frequently studied conditions of children were developmental disorders, asthma, and atopic dermatitis, accounting for over 40% of the studies. Nearly 44% used generic instruments, 60% of studies used caregiver-specific instruments, and only 2.7% employed both. No preference-based measure (PBM) developed for caregivers of children was identified; existing PBMs target caregivers of adult patients. This review shows increasing attention to caregiver QOL in pediatric research, reflected by the increasing number of recent publications. However, it reveals that current evidence remains concentrated on common conditions and is reliant on generic or highly disease-specific instruments. To advance inclusive and evidence-based pediatric care and policy, future studies should broaden disease coverage, adopt more rigorous designs, and develop validated PBMs for caregiving contexts.